BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Uetrecht J. Mechanistic Studies of Idiosyncratic DILI: Clinical Implications. Front Pharmacol 2019;10:837. [PMID: 31402866 DOI: 10.3389/fphar.2019.00837] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
Number Citing Articles
1 Teschke R, Danan G. Idiosyncratic Drug Induced Liver Injury, Cytochrome P450, Metabolic Risk Factors and Lipophilicity: Highlights and Controversies. Int J Mol Sci 2021;22:3441. [PMID: 33810530 DOI: 10.3390/ijms22073441] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
2 Wei S, Ma W, Zhang B, Li W. NLRP3 Inflammasome: A Promising Therapeutic Target for Drug-Induced Toxicity. Front Cell Dev Biol 2021;9:634607. [PMID: 33912556 DOI: 10.3389/fcell.2021.634607] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Teschke R, Danan G. Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993-Mid 2020: A Comprehensive Analysis. Medicines (Basel) 2020;7:E62. [PMID: 33003400 DOI: 10.3390/medicines7100062] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
4 Sernoskie SC, Jee A, Uetrecht JP. The Emerging Role of the Innate Immune Response in Idiosyncratic Drug Reactions. Pharmacol Rev 2021;73:861-96. [PMID: 34016669 DOI: 10.1124/pharmrev.120.000090] [Reference Citation Analysis]
5 Wang Y, Xu G, Wang Z, Li R, Zhan X, Liu H, Qin Q, Li W, Wang X, Zhang M, Tang J, Bai Z, Xiao X. Psoralidin, a major component of Psoraleae Fructus, induces inflammasome activation and idiosyncratic liver injury. Int Immunopharmacol 2021;92:107352. [PMID: 33422760 DOI: 10.1016/j.intimp.2020.107352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ozawa S, Miura T, Terashima J, Habano W, Ishida S. Recent Progress in Prediction Systems for Drug-induced Liver Injury Using in vitro Cell Culture. Drug Metab Lett 2020. [PMID: 33267768 DOI: 10.2174/1872312814666201202112610] [Reference Citation Analysis]
7 Ikeyama Y, Sato T, Takemura A, Sekine S, Ito K. Hypoxia/reoxygenation exacerbates drug-induced cytotoxicity by opening mitochondrial permeability transition pore: Possible application for toxicity screening. Toxicol In Vitro 2020;67:104889. [PMID: 32417306 DOI: 10.1016/j.tiv.2020.104889] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Liu W, Zeng X, Liu Y, Liu J, Li C, Chen L, Chen H, Ouyang D. The Immunological Mechanisms and Immune-Based Biomarkers of Drug-Induced Liver Injury. Front Pharmacol 2021;12:723940. [PMID: 34721020 DOI: 10.3389/fphar.2021.723940] [Reference Citation Analysis]
9 Wang J, Bwayi M, Gee RRF, Chen T. PXR-mediated idiosyncratic drug-induced liver injury: mechanistic insights and targeting approaches. Expert Opin Drug Metab Toxicol 2020;16:711-22. [PMID: 32500752 DOI: 10.1080/17425255.2020.1779701] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Hwang S, Yang YM. Exosomal microRNAs as diagnostic and therapeutic biomarkers in non-malignant liver diseases. Arch Pharm Res 2021;44:574-87. [PMID: 34165701 DOI: 10.1007/s12272-021-01338-2] [Reference Citation Analysis]
11 Meunier L, Larrey D. Drug-Induced Liver Injury: Biomarkers, Requirements, Candidates, and Validation. Front Pharmacol 2019;10:1482. [PMID: 31920666 DOI: 10.3389/fphar.2019.01482] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
12 Lewis JH, Cottu PH, Lehr M, Dick E, Shearer T, Rencher W, Bexon AS, Campone M, Varga A, Italiano A. Onapristone Extended Release: Safety Evaluation from Phase I-II Studies with an Emphasis on Hepatotoxicity. Drug Saf 2020;43:1045-55. [PMID: 32594454 DOI: 10.1007/s40264-020-00964-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Li Y, Ren Q, Wu D, Zhang M, Wang X, Zhu H, Sun S, Feng F. Combined 5-hydroxymethylcytosine content of human leucocyte antigen-B and human leucocyte antigen-DQB1 as novel biomarker for anti-tuberculosis drug-induced liver injury. Basic Clin Pharmacol Toxicol 2020;127:234-40. [PMID: 32180347 DOI: 10.1111/bcpt.13401] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Girish C, Sanjay S. Role of immune dysfunction in drug induced liver injury. World J Hepatol 2021; 13(11): 1677-1687 [PMID: 34904037 DOI: 10.4254/wjh.v13.i11.1677] [Reference Citation Analysis]
15 Hedenmalm K, Pacurariu A, Slattery J, Kurz X, Candore G, Flynn R. Is There an Increased Risk of Hepatotoxicity with Metamizole? A Comparative Cohort Study in Incident Users. Drug Saf 2021;44:973-85. [PMID: 34273099 DOI: 10.1007/s40264-021-01087-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Yang Z. Achieving a low human dose for targeted covalent drugs: Pharmacokinetic and pharmacodynamic considerations on target characteristics and drug attributes. Biopharm Drug Dispos 2021;42:150-9. [PMID: 33547681 DOI: 10.1002/bdd.2263] [Reference Citation Analysis]
17 Teschke R, Danan G. Idiosyncratic Drug-Induced Liver Injury (DILI) and Herb-Induced Liver Injury (HILI): Diagnostic Algorithm Based on the Quantitative Roussel Uclaf Causality Assessment Method (RUCAM). Diagnostics (Basel) 2021;11:458. [PMID: 33800917 DOI: 10.3390/diagnostics11030458] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
18 Vazquez JH, Clemens MM, Allard FD, Yee EU, Kennon-McGill S, Mackintosh SG, Jaeschke H, Hambuchen MD, McGill MR. Identification of Serum Biomarkers to Distinguish Hazardous and Benign Aminotransferase Elevations. Toxicol Sci 2020;173:244-54. [PMID: 31651977 DOI: 10.1093/toxsci/kfz222] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
19 Teschke R, Uetrecht J. Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues. Ann Transl Med 2021;9:730. [PMID: 33987428 DOI: 10.21037/atm-2020-ubih-05] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Wu X, Zhang Y, Qiu J, Xu Y, Zhang J, Huang J, Bai J, Huang Z, Qiu X, Xu W. Lipidomics Analysis Indicates Disturbed Hepatocellular Lipid Metabolism in Reynoutria multiflora-Induced Idiosyncratic Liver Injury. Front Pharmacol 2020;11:569144. [PMID: 33408629 DOI: 10.3389/fphar.2020.569144] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Teschke R, Vongdala N, Quan NV, Quy TN, Xuan TD. Metabolic Toxification of 1,2-Unsaturated Pyrrolizidine Alkaloids Causes Human Hepatic Sinusoidal Obstruction Syndrome: The Update. Int J Mol Sci 2021;22:10419. [PMID: 34638760 DOI: 10.3390/ijms221910419] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Oda S, Uchida Y, Aleo MD, Koza-Taylor PH, Matsui Y, Hizue M, Marroquin LD, Whritenour J, Uchida E, Yokoi T. An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol 2021;95:149-68. [PMID: 32816093 DOI: 10.1007/s00204-020-02882-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
23 Gao Y, Xu G, Ma L, Shi W, Wang Z, Zhan X, Qin N, He T, Guo Y, Niu M, Wang J, Bai Z, Xiao X. Icariside I specifically facilitates ATP or nigericin-induced NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity. Cell Commun Signal 2021;19:13. [PMID: 33573688 DOI: 10.1186/s12964-020-00647-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Yang CX, Yao DM. Research advances in pathogenesis and diagnostic markers of drug-induced liver injury. Shijie Huaren Xiaohua Zazhi 2021; 29(13): 726-732 [DOI: 10.11569/wcjd.v29.i13.726] [Reference Citation Analysis]
25 Li CY, Niu M, Liu YL, Tang JF, Chen W, Qian G, Zhang MY, Shi YF, Lin JZ, Li XJ, Li RS, Xiao XH, Li GH, Wang JB. Screening for Susceptibility-Related Factors and Biomarkers of Xianling Gubao Capsule-Induced Liver Injury. Front Pharmacol 2020;11:810. [PMID: 32547402 DOI: 10.3389/fphar.2020.00810] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Woolbright BL. Inflammation: Cause or consequence of chronic cholestatic liver injury. Food Chem Toxicol. 2020;137:111133. [PMID: 31972189 DOI: 10.1016/j.fct.2020.111133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
27 Villanueva-Paz M, Morán L, López-Alcántara N, Freixo C, Andrade RJ, Lucena MI, Cubero FJ. Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice. Antioxidants (Basel) 2021;10:390. [PMID: 33807700 DOI: 10.3390/antiox10030390] [Reference Citation Analysis]
28 Cho T, Wang X, Yeung K, Cao Y, Uetrecht J. Liver Injury Caused by Green Tea Extract in PD-1-/- Mice: An Impaired Immune Tolerance Model for Idiosyncratic Drug-Induced Liver Injury. Chem Res Toxicol 2021;34:849-56. [PMID: 33617238 DOI: 10.1021/acs.chemrestox.0c00485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Yadav AS, Shah NR, Carlson TJ, Driscoll JP. Metabolite Profiling and Reaction Phenotyping for the in Vitro Assessment of the Bioactivation of Bromfenac †. Chem Res Toxicol 2020;33:249-57. [PMID: 31815452 DOI: 10.1021/acs.chemrestox.9b00268] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Firman JW, Pestana CB, Rathman JF, Vinken M, Yang C, Cronin MTD. A Robust, Mechanistically Based In Silico Structural Profiler for Hepatic Cholestasis. Chem Res Toxicol 2021;34:641-55. [PMID: 33314907 DOI: 10.1021/acs.chemrestox.0c00465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Ahn JH, Jegal H, Choi MS, Kim S, Park SM, Ahn J, Han HY, Cho HS, Yoon S, Oh JH. TNFα enhances trovafloxacin-induced in vitro hepatotoxicity by inhibiting protective autophagy. Toxicol Lett 2021;342:73-84. [PMID: 33609687 DOI: 10.1016/j.toxlet.2021.02.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]